Evidence map›Paper›PMID 26107110›Full record

ArticleSmall GTPases2015

RABGTPases in MT1-MMP trafficking and cell invasion: Physiology versus pathology.

Stefan Linder, Giorgio Scita

Open access · bronzeAbstract read
In one paragraph

Article in Small GTPases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Cancer cell extravasation requiresBritish journal of cancer · 2024
    Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Invadopodia: clearing the way for cancer cell invasion.Annals of translational medicine · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Intracellular Transport in Cancer Metabolic Reprogramming.Frontiers in cell and developmental biology · 2020
    Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Stefan Lindera Institute for Medical Microbiology; Virology and Hygiene ; University Medical Center Eppendorf ; Hamburg , Germany.
Giorgio Scita
FIRC Institute of Molecular Oncology · ITUniversity Medical Center Hamburg-Eppendorf · DE

Funding

European Research Council 268836
6 · The paper itself

Abstract

The matrix metalloproteinase MT1-MMP is a central regulator of cell invasion in both physiological and pathological settings, such as tissue surveillance by immune cells and cancer cell metastasis. MT1-MMP cleaves a plethora of intra- and extracellular proteins, including extracellular matrix proteins, matrix receptors, and also other MMPs, and thus enables modification of both the cell surface proteome and the pericellular environment. Despite its importance for cell invasion, the pathways regulating MT1-MMP exposure on the cell surface are largely unknown. Recently, our groups discovered that a specific subset of RABGTPases, most notably RAB5a, is critical for MT1-MMP trafficking in primary human macrophages and carcinoma cells. Here, we discuss and contrast our findings for both cell types, pointing out common features and differences in the RABGTPase-dependent trafficking of MT1-MMP in health and disease.

Indexed as

AnimalsCell MembraneCell MovementCells, CulturedExtracellular MatrixHumansMacrophagesMatrix Metalloproteinase 14Neoplasm InvasivenessNeoplasmsProtein Transportrab GTP-Binding ProteinsMatrix Metalloproteinase 14MMP14 protein, humanrab GTP-Binding Proteinscarcinoma cellscell invasionintracellular traffickinginvadopodiamacrophagesMT1-MMPpodosomesRABGTPasesvesicles

Identifiers

PMID26107110
PMCPMC4601268
OpenAlexW1919266471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.